FDA recall D-0508-2026
Wells Pharma of Houston LLC · Class II · drug
Product
fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.
Reason for recall
cGMP deviations.
Distribution
U.S. Nationwide.
Key facts
- Status
- Ongoing
- Initiation date
- 2026-04-01
- Report date
- 2026-05-06
- Voluntary/Mandated
- Voluntary: Firm initiated
- Location
- Houston, TX, United States
Primary source
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0508-2026